PL3442583T3 - Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa - Google Patents

Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa

Info

Publication number
PL3442583T3
PL3442583T3 PL17782003.2T PL17782003T PL3442583T3 PL 3442583 T3 PL3442583 T3 PL 3442583T3 PL 17782003 T PL17782003 T PL 17782003T PL 3442583 T3 PL3442583 T3 PL 3442583T3
Authority
PL
Poland
Prior art keywords
nicotine
nasal
composition
treating bleeding
paranasal mucosa
Prior art date
Application number
PL17782003.2T
Other languages
English (en)
Inventor
Arturo Solis Herrera
Original Assignee
Arturo Solis Herrera
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901359A external-priority patent/AU2016901359A0/en
Application filed by Arturo Solis Herrera filed Critical Arturo Solis Herrera
Publication of PL3442583T3 publication Critical patent/PL3442583T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • A61N5/0603Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0607Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • A61N5/0603Apparatus for use inside the body for treatment of body cavities

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17782003.2T 2016-04-12 2017-04-12 Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa PL3442583T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901359A AU2016901359A0 (en) 2016-04-12 Application of Nicotine Compounds to Nasal Membranes
PCT/IB2017/000764 WO2017178897A2 (en) 2016-04-12 2017-04-12 Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
PL3442583T3 true PL3442583T3 (pl) 2024-08-19

Family

ID=60042487

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17782003.2T PL3442583T3 (pl) 2016-04-12 2017-04-12 Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa

Country Status (15)

Country Link
US (1) US10639300B2 (pl)
EP (1) EP3442583B1 (pl)
JP (1) JP6770091B2 (pl)
KR (1) KR102199560B1 (pl)
CN (1) CN109069649A (pl)
AU (1) AU2017250514B2 (pl)
BR (1) BR122023020807A2 (pl)
CA (1) CA3014725C (pl)
ES (1) ES2984490T3 (pl)
HK (1) HK1258883A1 (pl)
MX (1) MX389596B (pl)
NZ (1) NZ744942A (pl)
PL (1) PL3442583T3 (pl)
RU (1) RU2718061C1 (pl)
WO (1) WO2017178897A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096932B2 (en) * 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
CN116251080A (zh) * 2023-02-16 2023-06-13 杭州师范大学 茄尼醇在制备预防、治疗或缓解慢性疼痛药物中的应用
CN120078753A (zh) * 2023-12-01 2025-06-03 北京生命科技研究院有限公司 茄尼醇在制备预防和/或治疗皮炎的药物中的用途
EP4623920A4 (en) * 2024-02-16 2026-04-08 Catholic Univ Korea Ind Academic Cooperation Foundation Pharmaceutical composition comprising inferior nasal turbinate stem cells as the active ingredient for the prevention or treatment of secondary atrophic rhinitis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
MA23588A1 (fr) * 1994-06-23 1995-12-31 Procter & Gamble Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
HU224941B1 (en) 2001-08-10 2006-04-28 Bgi Innovacios Kft Phototerapy apparatus
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
ES2462545T3 (es) 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
ES2321721T3 (es) 2003-09-08 2009-06-10 Mcneil Ab Formulaciones de nicotina y uso de las mismas.
RU2414461C2 (ru) 2004-07-15 2011-03-20 Юниверсите Лаваль Агонисты рецепторов никотина и способы их применения для лечения воспалительных заболеваний
BRPI0621650A2 (pt) 2006-05-08 2011-12-20 Arturo Solis Herrera composições farmacêuticas que induzem a liberação do alfa-msh endogênico a partir de células-tronco, e usos de uma substáncia ativa que induz a referida liberação e de alfa-msh sintetizado por qualquer meio
WO2008062453A2 (en) * 2006-09-25 2008-05-29 Nikki Nikhilesh Singh Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US9744375B2 (en) * 2010-08-05 2017-08-29 Allergia, Inc. Apparatus and methods for controlling and applying flash lamp radiation
KR102957402B1 (ko) * 2013-12-05 2026-04-24 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 액제 및 그 방법
CN104706556A (zh) * 2015-03-31 2015-06-17 苏州维泰生物技术有限公司 抗过敏组合物及其在化妆品中的应用

Also Published As

Publication number Publication date
HK1258883A1 (zh) 2019-11-22
CA3014725A1 (en) 2017-10-19
JP6770091B2 (ja) 2020-10-14
ES2984490T3 (es) 2024-10-29
RU2718061C1 (ru) 2020-03-30
CA3014725C (en) 2020-09-22
KR102199560B1 (ko) 2021-01-07
BR122023020807A2 (pt) 2023-12-12
EP3442583A2 (en) 2019-02-20
AU2017250514A1 (en) 2018-08-23
EP3442583A4 (en) 2019-12-25
WO2017178897A3 (en) 2017-11-23
KR20180108821A (ko) 2018-10-04
CN109069649A (zh) 2018-12-21
NZ744942A (en) 2020-08-28
WO2017178897A2 (en) 2017-10-19
US20190111038A1 (en) 2019-04-18
MX2018012439A (es) 2019-02-21
EP3442583C0 (en) 2024-04-10
MX389596B (es) 2025-03-20
BR112018067718A2 (pt) 2019-01-08
JP2019511520A (ja) 2019-04-25
US10639300B2 (en) 2020-05-05
AU2017250514B2 (en) 2019-12-19
EP3442583B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
IL261469A (en) Devices for vaporizing and inhaling nicotine
IL264156A (en) Compounds, preparations and methods for treating the disease
EP3400815A4 (en) GESCHMACKSINHALATOR
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
EP3498297C0 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
EP3377068C0 (en) COMBINATION THERAPY COMPRISING TETRACYCLIC QUINOLONE ANALOGUES FOR THE TREATMENT OF CANCER
IL256056A (en) Ezh2 inhibitors for treating lymphoma
IL256684B (en) Medicinal compounds and preparations for the treatment of social disorders and substance use disorders
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
SI3302573T1 (sl) Sestavek za zdravljenje možganskih lezij
IL249640A0 (en) Preparations for the treatment of nosebleeds
EP3303556C0 (en) COMPOSITIONS FOR THE TREATMENT OF OSTEO-CARTILAGINOUS DISORDERS
GB201612043D0 (en) Composition for treatment of disorders
SI3302523T1 (sl) Sestavek za zdravljenje tkivnih lezij
EP3375450A4 (en) COMPOSITION FOR THE TREATMENT OF APOPLEXIA OVER NASAL ADMINISTRATION
EP3442583C0 (en) COMPOSITION COMPRISING NICOTINE FOR TREATING BLEEDING FROM THE NASAL OR PARANASAL MUCOSA
PL3261683T3 (pl) Kompozycja do stosowania miejscowego do leczenia uszkodzeń błony śluzowej
SG11202002088TA (en) Methods and compositions for treating chronic lung diseases
IL253878A0 (en) An effective substance for the treatment of respiratory inflammation
PL3285791T3 (pl) Kompozycja do leczenia gardła/jamy gardłowej
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
PL3482761T3 (pl) Kompozycje zawierające kwas kromoglikanowy do leczenia zapalenia skóry